 | • レポートコード：MRC2211A085 • 出版社/出版日：Transparency Market Research / 2022年9月 • レポート形態：英文、PDF、199ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| トレンスペアレンシーマーケットリサーチ社の当調査レポートでは、世界の非侵襲的出生前検査（NIPT）市場を総合的に調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、検査種類別（Materni21、ハーモニー、パノラマ、Verifi、NIFTY、その他）分析、技術別（NGS、WGS、その他）分析、用途別（トリソミー症候群、微小欠失症候群、その他）分析、エンドユーザー別（病院、診断研究室、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの内容を掲載しています。なお、当書には、Berry Genetics、BGI、Laboratory Corporation of America Holdings、Agilent Technologies, Inc.、Illumina, Inc.、F. Hoffmann-La Roche Ltd.、PerkinElmer, Inc.、Eurofins LifeCodexx AG、QIAGEN、IGENOMIX、Pacific Biosciences、Natera, Inc.などの企業情報が含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界の非侵襲的出生前検査（NIPT）市場規模：検査種類別 - Materni21検査の市場規模 - ハーモニー検査の市場規模 - パノラマ検査の市場規模 - Verifi検査の市場規模 - NIFTY検査の市場規模 ・世界の非侵襲的出生前検査（NIPT）市場規模：技術別 - NGS技術の市場規模 - WGS技術の市場規模 - その他技術の市場規模 ・世界の非侵襲的出生前検査（NIPT）市場規模：用途別 - トリソミー症候群における市場規模 - 微小欠失症候群における市場規模 - その他用途における市場規模 ・世界の非侵襲的出生前検査（NIPT）市場規模：エンドユーザー別 - 病院における市場規模 - 診断研究室における市場規模 - その他エンドユーザーにおける市場規模 ・世界の非侵襲的出生前検査（NIPT）市場規模：地域別 - 北米の非侵襲的出生前検査（NIPT）市場規模 - ヨーロッパの非侵襲的出生前検査（NIPT）市場規模 - アジア太平洋の非侵襲的出生前検査（NIPT）市場規模 - 中南米の非侵襲的出生前検査（NIPT）市場規模 - 中東・アフリカの非侵襲的出生前検査（NIPT）市場規模 ・競争状況 |
Non-invasive Prenatal Testing Market – Scope of Report
TMR’s report on the global non-invasive prenatal testing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global non-invasive prenatal testing market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global non-invasive prenatal testing market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the non-invasive prenatal testing market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global non-invasive prenatal testing market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global non-invasive prenatal testing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global non-invasive prenatal testing market.
The report delves into the competitive landscape of the global non-invasive prenatal testing market. Key players operating in the global non-invasive prenatal testing market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global non-invasive prenatal testing market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market non-invasive prenatal testing.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Non-invasive Prenatal Testing Market
4. Market Overview
4.1. Introduction
4.1.1. Test Type Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Non-invasive Prenatal Testing Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industry Evolution/Developments
5.2. Cost Comparison Analysis
5.3. Advancement in NIPT
5.4. Covid 19 Impact Analysis
6. Global Non-invasive Prenatal Testing Market Analysis and Forecast, by Test Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Test Type, 2017–2031
6.3.1. Materni21
6.3.2. Harmony
6.3.3. Panorama
6.3.4. Verifi
6.3.5. NIFTY
6.3.6. Others
6.4. Market Attractiveness Analysis, by Test Type
7. Global Non-invasive Prenatal Testing Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Trisomy
7.3.2. Micro-deletions Symptoms
7.3.3. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Non-invasive Prenatal Testing Market Analysis and Forecast, by Technology
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Technology, 2017–2031
8.3.1. NGS
8.3.2. WGS
8.3.3. Others
8.4. Market Attractiveness Analysis, by Technology
9. Global Non-invasive Prenatal Testing Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Diagnostic Laboratories
9.3.3. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Non-invasive Prenatal Testing Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Non-invasive Prenatal Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Test Type, 2017–2031
11.2.1. Materni21
11.2.2. Harmony
11.2.3. Panorama
11.2.4. Verifi
11.2.5. NIFTY
11.2.6. Others
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Trisomy
11.3.2. Micro-deletions Symptoms
11.3.3. Others
11.4. Market Value Forecast, by Technology, 2017–2031
11.4.1. NGS
11.4.2. WGS
11.4.3. Others
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospitals
11.5.2. Diagnostic Laboratories
11.5.3. Others
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Test Type
11.7.2. By Application
11.7.3. By Technology
11.7.4. By End-user
11.7.5. By Country
12. Europe Non-invasive Prenatal Testing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Test Type, 2017–2031
12.2.1. Materni21
12.2.2. Harmony
12.2.3. Panorama
12.2.4. Verifi
12.2.5. NIFTY
12.2.6. Others
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Trisomy
12.3.2. Micro-deletions Symptoms
12.3.3. Others
12.4. Market Value Forecast, by Technology, 2017–2031
12.4.1. NGS
12.4.2. WGS
12.4.3. Others
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospitals
12.5.2. Diagnostic Laboratories
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Test Type
12.7.2. By Application
12.7.3. By Technology
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Non-invasive Prenatal Testing Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Test Type, 2017–2031
13.2.1. Materni21
13.2.2. Harmony
13.2.3. Panorama
13.2.4. Verifi
13.2.5. NIFTY
13.2.6. Others
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Trisomy
13.3.2. Micro-deletions Symptoms
13.3.3. Others
13.4. Market Value Forecast, by Technology, 2017–2031
13.4.1. NGS
13.4.2. WGS
13.4.3. Others
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Hospitals
13.5.2. Diagnostic Laboratories
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Test Type
13.7.2. By Application
13.7.3. By Technology
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Non-invasive Prenatal Testing Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Test Type, 2017–2031
14.2.1. Materni21
14.2.2. Harmony
14.2.3. Panorama
14.2.4. Verifi
14.2.5. NIFTY
14.2.6. Others
14.3. Market Value Forecast, by Application, 2017–2031
14.3.1. Trisomy
14.3.2. Micro-deletions Symptoms
14.3.3. Others
14.4. Market Value Forecast, by Technology, 2017–2031
14.4.1. NGS
14.4.2. WGS
14.4.3. Others
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospitals
14.5.2. Diagnostic Laboratories
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Test Type
14.7.2. By Application
14.7.3. By Technology
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Non-invasive Prenatal Testing Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Test Type, 2017–2031
15.2.1. Materni21
15.2.2. Harmony
15.2.3. Panorama
15.2.4. Verifi
15.2.5. NIFTY
15.2.6. Others
15.3. Market Value Forecast, by Application, 2017–2031
15.3.1. Trisomy
15.3.2. Micro-deletions Symptoms
15.3.3. Others
15.4. Market Value Forecast, by Technology, 2017–2031
15.4.1. NGS
15.4.2. WGS
15.4.3. Others
15.5. Market Value Forecast, by End-user, 2017–2031
15.5.1. Hospitals
15.5.2. Diagnostic Laboratories
15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Test Type
15.7.2. By Application
15.7.3. By Technology
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2021
16.3. Company Profiles
16.3.1. Berry Genetics
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Financial Analysis
16.3.1.3. Growth Strategies
16.3.1.4. SWOT Analysis
16.3.2. BGI
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Financial Analysis
16.3.2.3. Growth Strategies
16.3.2.4. SWOT Analysis
16.3.3. Laboratory Corporation of America Holdings
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Financial Analysis
16.3.3.3. Growth Strategies
16.3.3.4. SWOT Analysis
16.3.4. Agilent Technologies, Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Financial Analysis
16.3.4.3. Growth Strategies
16.3.4.4. SWOT Analysis
16.3.5. Illumina, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Financial Analysis
16.3.5.3. Growth Strategies
16.3.5.4. SWOT Analysis
16.3.6. F. Hoffmann-La Roche Ltd.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Financial Analysis
16.3.6.3. Growth Strategies
16.3.6.4. SWOT Analysis
16.3.7. PerkinElmer, Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Financial Analysis
16.3.7.3. Growth Strategies
16.3.7.4. SWOT Analysis
16.3.8. Eurofins LifeCodexx AG
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Financial Analysis
16.3.8.3. Growth Strategies
16.3.8.4. SWOT Analysis
16.3.9. QIAGEN
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Financial Analysis
16.3.9.3. Growth Strategies
16.3.9.4. SWOT Analysis
16.3.10. IGENOMIX
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Financial Analysis
16.3.10.3. Growth Strategies
16.3.10.4. SWOT Analysis
16.3.11. Pacific Biosciences
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Financial Analysis
16.3.11.3. Growth Strategies
16.3.11.4. SWOT Analysis
16.3.12. Natera, Inc.
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Financial Analysis
16.3.12.3. Growth Strategies
16.3.12.4. SWOT Analysis
Table 01: Global Non-invasive Prenatal Testing Market Value Share, by Test Type, 2021
Table 02: Global Non-invasive Prenatal Testing Market Value Share, by Application, 2021
Table 03: Global Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 04: Global Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 05: Global Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 06: Global Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 07: Global Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 08: North America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 09: North America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 10: North America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 11: North America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 12: North America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 13: Europe Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 14: Europe Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 15: Europe Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 16: Europe Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 17: Europe Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Asia Pacific Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 19: Asia Pacific Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 20: Asia Pacific Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 21: Asia Pacific Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 22: Asia Pacific Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 23: Latin America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 24: Latin America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 25: Latin America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 26: Latin America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 27: Latin America Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 28: Middle East & Africa Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031
Table 29: Middle East & Africa Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 30: Middle East & Africa Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 31: Middle East & Africa Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 32: Middle East & Africa Non-invasive Prenatal Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031